Ariel Hurley Sells 3,203 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 3,203 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares in the company, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Ariel Hurley also recently made the following trade(s):

• On Monday, January 13th, Ariel Hurley sold 2,250 shares of Blueprint Medicines stock. The stock was sold at an average price of $100.00, for a total value of $225,000.00.
• On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The stock was sold at an average price of $93.26, for a total value of $169,639.94.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock traded down $0.37 during trading hours on Tuesday, reaching $89.38. The stock had a trading volume of 1,385,852 shares, compared to its average volume of 1,018,106. The stock’s 50 day moving average is $99.52 and its 200 day moving average is $94.37. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a twelve month low of $80.68 and a twelve month high of $121.90. The firm has a market capitalization of $5.71 billion, a PE ratio of -82.76 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on BPMC. StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday. HC Wainwright restated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. Piper Sandler lifted their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Finally, Wedbush restated an “outperform” rating and issued a $128.00 target price on shares of Blueprint Medicines in a research note on Friday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $123.83.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in Blueprint Medicines by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,291 shares of the biotechnology company’s stock worth $212,000 after acquiring an additional 422 shares in the last quarter. US Bancorp DE grew its position in shares of Blueprint Medicines by 147.6% in the third quarter. US Bancorp DE now owns 11,971 shares of the biotechnology company’s stock valued at $1,107,000 after purchasing an additional 7,137 shares during the period. M&G PLC purchased a new stake in shares of Blueprint Medicines during the third quarter worth about $9,101,000. Covestor Ltd raised its position in shares of Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 403 shares during the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth about $999,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.